Sánchez UJT

Language: Spanish
References: 24
Page: 58-64
PDF size: 249.29 Kb.

ABSTRACT

The sleep apnea/hypopnea syndrome currently represents one of the most significant risk factors for cardiovascular disease, from being considered the second most frequent cause of secondary systemic arterial hypertension to being a risk factor for sudden death in both arrhythmias and heart failure. It is essential not only to adequately diagnose the apnea-hypopnea syndrome, but also to properly characterize it, to clearly define which are the etiological mechanisms that lead to it, both anatomical and mechanical, and to carry out an appropriate quantification. Continuous positive pressure is a useful treatment for this type of entity, although it has a serious adherence problem; it must be stressed that it is not the ideal treatment for all patients and that it is essential to make an appropriate indication for each of the therapeutic modalities.

REFERENCES

1. Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol. 2017; 69 (7): 841-858.

2. Lyons OD, Bradley TD. Heart failure and sleep apnea. Can J Cardiol. 2015; 31 (7): 898-908.

3. Cowie MR. Sleep apnea: state of the art. Trends Cardiovasc Med. 2017; 27: 280-289.

4. Dempsey JA, Veasey SC, Morgan BJ, O’Donnell CP. Pathophysiology of sleep apnea. Physiol Rev. 2010; 90: 47-112.

5. Sommers V, Javaheri S. Cardiovascular effects of sleep-related breathing disorders. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 6th edition. Philadelphia, PA: Elsevier; 2017. pp. 1243-1252.

6. Yaggi HK, Araujo AB, McKinlay JB. Sleep duration as a risk factor for the development of type 2 diabetes. Diabetes Care. 2006; 29: 657-661.

7. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000; 342 (19): 1378-1384.

8. Nieto FJ, Young T, Lind BK. Association of sleep-disordered breathing, sleep apnea and hypertension in a large community-based study. Sleep Heart Health Study. JAMA. 2000; 283 (14): 1829-1836.

9. Gonçalves SC, Martinez D, Gus M, de Abreu-Silva EO, Bertoluci C, Dutra I et al. Obstructive sleep apnea and resistant hypertension: a case-control study. Chest. 2007; 132 (6): 1858-1862.

10. Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, McCarthy K et al. Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol. 2009; 104 (9): 1300-1306.

11. Arias MA, García-Río F, Alonso-Fernández A, Martínez I, Villamor J. Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: a randomized, controlled cross-over study. Eur Heart J. 2006; 27 (9): 1106-1113.

12. Fein AS, Shvilkin A, Shah D, Haffajee CI, Das S, Kumar K et al. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol. 2013; 62 (4): 300-305.

13. Gami AS, Olson EJ, Shen WK, Wright RS, Ballman KV, Hodge DO et al. Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults. J Am Coll Cardiol. 2013; 62 (7): 610-616.

14. Peker Y, Carlson J, Hedner J. Increased incidence of coronary artery disease in sleep apnoea: a long-term follow-up. Eur Respir J. 2006; 28 (3): 596-602.

15. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005; 365 (9464): 1046-1053.

16. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med. 2016; 375 (10): 919-931.

17. Lanfranchi PA, Somers VK, Braghiroli A, Corrá U, Eleuteri E, Giannuzzi P. Central sleep apnea in left ventricular dysfunction: prevalence and implications for arrhythmic risk. Circulation. 2003; 107 (5): 727-732.

18. Oldenburg O, Wellmann B, Buchholz A, Bitter T, Fox H, Thiem U et al. Nocturnal hypoxaemia is associated with increased mortality in stable heart failure patients. Eur Heart J. 2016; 37 (21): 1695-1703.

19. Javaheri S, Caref EB, Chen E, Tong KB, Abraham WT. Sleep apnea testing and outcomes in a large cohort of Medicare beneficiaries with newly diagnosed heart failure. Am J Respir Crit Care Med. 2011; 183 (4): 539-546.

20. Cowie MR, Woehrle H, Wegscheider K, Angermann C, d’Ortho MP, Erdmann E et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med. 2015; 373 (12): 1095-1105.

21. Javaheri S. Pembrey’s dream: the time has come for a long-term trial of nocturnal supplemental nasal oxygen to treat central sleep apnea in congestive heart failure. Chest. 2003; 123 (2): 322-325.

22. Costanzo MR, Ponikowski P, Javaheri S, Augostini R, Goldberg L, Holcomb R et al. Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. Lancet. 2016; 388 (10048): 974-982.

23. Barbé F, Durán-Cantolla J, Sánchez-de-la-Torre M, Martínez-Alonso M, Carmona C, Barceló A et al. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. JAMA. 2012; 307 (20): 2161-2168.

24. Peker Y, Glantz H, Eulenburg C, Wegscheider K, Herlitz J, Thunström E. Effect of positive airway pressure on cardiovascular outcomes in coronary artery disease patients with nonsleepy obstructive sleep apnea. The RICCADSA randomized controlled trial. Am J Respir Crit Care Med. 2016; 194 (5): 613-620.